- Home
- MANE vs LQDA Comparison
MANE vs LQDA Comparison
Compare MANE & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MANE | LQDA |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.8B |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MANE | LQDA |
|---|---|---|
| Price | $139.63 | $45.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $170.50 | $54.38 |
| AVG Volume (30 Days) | 784.2K | ★ 5.5M |
| Earning Date | 11-10-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | N/A | ★ 1.26 |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | N/A | $357.27 |
| Revenue Next Year | N/A | $1.34 |
| P/E Ratio | ★ N/A | $35.65 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $35.43 | $22.22 |
| 52 Week High | $146.58 | $93.61 |
Technical Indicators
Market Signals| Indicator | MANE | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 51.26 |
| Support Level | $92.62 | $35.00 |
| Resistance Level | N/A | $46.67 |
| Average True Range (ATR) | 7.62 | 2.88 |
| MACD | 1.38 | 2.62 |
| Stochastic Oscillator | 80.00 | 89.61 |
Price Performance
Historical ComparisonAbout MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.